Article
SVR Achieved With 8-Week Course in Coinfected Hepatitis C Patients
Encouraging results with a shorter course of hepatitis C treatment were presented at the Digestive Disease Week meeting. Patients receiving an 8-week course of sofosbuvir and daclatasvir, previously naïve to direct-acting antiviral treatment, achieved a sustained response at 12 weeks.
Results, presented at the Digestive Disease Week meeting, from HIV-coinfected hepatitis C virus (HCV) patients receiving an 8-week course of sofosbuvir and daclatasvir, previously naïve to direct-acting antiviral treatment., were encouraging The data showed that once-daily daclatasvir combined with sofosbuvir, administered for 8 weeks, achieved a sustained virologic response in more than 75% of patients, 12 weeks after finishing the course.
While the treatment was well-tolerated overall, post-treatment hepatitis C virus relapse occurred in 1% to 2% of patients in the 12-week treatment groups and in about 25% in the 8-week group.
Read the complete article on MedPage Today: http://bit.ly/1c94yhg
